Vigdis Nygaard

Norwegian Cancer Society

Papers

1

Total Citations

57

H-Index

1

About

Vigdis Nygaard is a prominent researcher in molecular oncology, with a primary focus on the transcriptional mechanisms underlying B-cell lymphomas. Her work has significantly advanced the understanding of splenic marginal zone lymphoma (SMZL), a rare and poorly understood malignancy. In her landmark 2004 study, Nygaard demonstrated the constitutive expression of AP-1 transcription factors—including c-jun, junD, junB, and c-fos—alongside the marginal zone B-cell transcription factor Notch2 in SMZL. This seminal finding, which has garnered 57 citations, provided the first molecular evidence linking aberrant AP-1 signaling and Notch2 dysregulation to the pathogenesis of this lymphoma. By identifying these key transcriptional drivers, Nygaard’s research has opened new avenues for targeted therapeutic strategies and improved diagnostic markers. Her contributions are widely recognized for bridging basic molecular biology and clinical oncology, offering critical insights into how transcription factor networks drive lymphoid malignancies. Nygaard’s work continues to influence studies on B-cell development and lymphoma biology, underscoring her lasting impact on the field.

Research Focus

Key Achievements

1
H-Index
1
Papers
57
Total Citations
57
Avg Citations/Paper
🏆 Most Cited Paper
Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma
57 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Norwegian Cancer Society

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago